Yantai Dongcheng Biochemicals announced that its subsidiary Lanana Cheng received a drug clinical trial approval notice from the National Medical Products Administration for 18F-LNC1007 injection and will soon conduct clinical trials. The drug is a new dual-target radiopharmaceutical that targets fibroblast activation protein (FAP) and integrin αvβ3 (αvβ3), intended for the diagnosis of FAP and αvβ3-positive solid tumors in adults. Currently, there are no similar products on the market domestically or internationally. As of now, the cumulative research and development expenses for the drug-related project have reached approximately 18.6938 million yuan. In accordance with relevant laws and regulations, after obtaining clinical trial approval, the drug still needs to undergo clinical trials. After successful clinical trials, it can be registered and declared according to the procedures, and can only be marketed after official evaluation and approval.
东诚药业：控股子公司获得药物临床试验批准通知书
Yantai Dongcheng Biochemicals: The holding subsidiary has obtained the Notice of Approval for Drug Clinical Trials.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.